
医学资讯AML1-ETODHX15突变
DHX15致癌突变驱动线粒体代谢,维持AML白血病干性
By MedXY|2026年8月27日
DHX15 R222G热点突变与AML1-ETO融合协同增强线粒体功能和白血病干细胞活性,导致AML预后更差及化疗耐药,并揭示OXPHOS抑制可能是一种有前景的靶向治疗策略。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.